{"id":"oxymetholone","rwe":[],"tags":[{"label":"oxymetholone","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Androgen receptor","category":"target"},{"label":"AR","category":"gene"},{"label":"ESR1","category":"gene"},{"label":"A14AA05","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Aplastic anemia","category":"indication"},{"label":"Congenital hypoplastic anemia","category":"indication"},{"label":"Hypoplastic anemia","category":"indication"},{"label":"Pharmobedient","category":"company"},{"label":"Approved 1970s","category":"decade"},{"label":"Anabolic Agents","category":"pharmacology"},{"label":"Androgens","category":"pharmacology"},{"label":"Hormones","category":"pharmacology"}],"phase":"marketed","safety":{"contraindications":["Arteriosclerotic vascular disease","Benign prostatic hyperplasia","Blood coagulation disorder","Breast Carcinoma in Males","Breastfeeding (mother)","Carcinoma of female breast","Chronic heart failure","Diabetes mellitus","Disease of liver","Disorder of coronary artery","Edema","Heart disease","Hepatic failure","Humoral hypercalcemia of malignancy","Hypercholesterolemia","Hypoalphalipoproteinemia","Kidney disease","Liver function tests abnormal","Neoplasm of prostate","Nephrotic syndrome","Peliosis hepatis","Pregnancy, function"]},"trials":[],"aliases":[],"company":"Pharmobedient","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=OXYMETHOLONE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T04:09:00.351513+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T04:09:06.162184+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=OXYMETHOLONE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T04:09:06.480403+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Androgen Receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T04:09:07.539757+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200585/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T04:09:07.196721+00:00"}},"allNames":"anadrol-50","offLabel":[],"synonyms":["oxymetholone","anasteron","anasteronal","nastenon","oxymethenolone","protanabol"],"timeline":[{"date":"1972-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from MEDA PHARMS to Pharmobedient"}],"aiSummary":"Anadrol-50 (OXYMETHOLONE) is a small molecule oxymetholone drug developed by MEDA PHARMS and currently owned by Pharmobedient. It targets the androgen receptor and was FDA-approved in 1972 for the treatment of aplastic anemia, congenital hypoplastic anemia, and hypoplastic anemia. As an off-patent medication, Anadrol-50 is no longer protected by patents, and its commercial status is generic. Key safety considerations include the potential for liver damage and other adverse effects. Anadrol-50 is a potent anabolic steroid that promotes muscle growth and red blood cell production.","approvals":[{"date":"1972-01-18","orphan":false,"company":"MEDA PHARMS","regulator":"FDA"}],"brandName":"Anadrol-50","ecosystem":[{"indication":"Aplastic anemia","otherDrugs":[{"name":"romiplostim","slug":"romiplostim","company":"Amgen"}],"globalPrevalence":null},{"indication":"Congenital hypoplastic anemia","otherDrugs":[{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"cortisone acetate","slug":"cortisone-acetate","company":""},{"name":"dexamethasone","slug":"dexamethasone","company":""},{"name":"hydrocortisone","slug":"hydrocortisone","company":"Merck"}],"globalPrevalence":null},{"indication":"Hypoplastic anemia","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Androgen receptor","novelty":"Follow-on","targets":[{"gene":"AR","source":"DrugCentral","target":"Androgen receptor","protein":"Androgen receptor"},{"gene":"ESR1","source":"DrugCentral","target":"Estrogen receptor","protein":"Estrogen receptor"}],"modality":"Small Molecule","drugClass":"oxymetholone","explanation":"","oneSentence":"","technicalDetail":"Anadrol-50 is a non-aromatizable, 17-alpha-alkylated anabolic steroid that binds to the androgen receptor (AR) with high affinity, activating downstream signaling pathways that promote protein synthesis, muscle growth, and erythropoiesis."},"commercial":{"launchDate":"1972","_launchSource":"DrugCentral (FDA 1972-01-18, MEDA PHARMS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2033","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=OXYMETHOLONE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=OXYMETHOLONE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:14:03.577141","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T04:09:08.758171+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"stanozolol","drugSlug":"stanozolol","fdaApproval":"1962-01-09","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"prasterone","drugSlug":"prasterone","fdaApproval":"","patentExpiry":"Mar 19, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"oxandrolone","drugSlug":"oxandrolone","fdaApproval":"1964-07-21","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"oxymetholone","indications":{"approved":[{"name":"Aplastic anemia","source":"DrugCentral","snomedId":306058006,"regulator":"FDA"},{"name":"Congenital hypoplastic anemia","source":"DrugCentral","snomedId":88854002,"regulator":"FDA"},{"name":"Hypoplastic anemia","source":"DrugCentral","snomedId":41614006,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Pharmobedient","drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"stanozolol","brandName":"stanozolol","genericName":"stanozolol","approvalYear":"1962","relationship":"same-class"},{"drugId":"prasterone","brandName":"prasterone","genericName":"prasterone","approvalYear":"","relationship":"same-class"},{"drugId":"oxandrolone","brandName":"oxandrolone","genericName":"oxandrolone","approvalYear":"1964","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05867641","phase":"NA","title":"VR&R: Providing Caregiver Respite by Managing BPSDs and Improving QoL in People with Dementia Using Immersive VR-Therapy","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-02-12","conditions":["Dementia"],"enrollment":50,"completionDate":"2027-02-01"},{"nctId":"NCT06095661","phase":"NA","title":"Virtual Reality as a Postoperative Pain Management Adjunct in Older Adults: An Acceptability and Feasibility Study","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2023-10-26","conditions":["Aged","Surgery","Pain, Postoperative","Virtual Reality"],"enrollment":29,"completionDate":"2024-06-01"},{"nctId":"NCT02553265","phase":"PHASE2","title":"Carbidopa for the Treatment of Excessive Blood Pressure Variability","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2015-09","conditions":["Dysautonomia, Familial","Baroreflex Failure Syndrome"],"enrollment":22,"completionDate":"2019-05-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000146758","MMSL":"5219","NDDF":"001255","UNII":"L76T0ZCA8K","VUID":"4018432","CHEBI":"CHEBI:7864","VANDF":"4018432","INN_ID":"1022","RXNORM":"7813","UMLSCUI":"C0030072","chemblId":"CHEMBL1200585","ChEMBL_ID":"CHEMBL1200585","KEGG_DRUG":"D00490","DRUGBANK_ID":"DB06412","PUBCHEM_CID":"5281034","SNOMEDCT_US":"126101002","MESH_DESCRIPTOR_UI":"D010110"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1972-","companyName":"Meda Pharms","relationship":"Original Developer"},{"period":"present","companyName":"Pharmobedient","relationship":"Current Owner"}],"publicationCount":324,"therapeuticAreas":["Hematology"],"atcClassification":{"source":"DrugCentral","atcCode":"A14AA05","allCodes":["A14AA05"]},"biosimilarFilings":[],"originalDeveloper":"Meda Pharms","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Pharmobedient","companyId":"pharmobedient","modality":"Small molecule","firstApprovalDate":"1972","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1972-01-18T00:00:00.000Z","mah":"MEDA PHARMS","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T04:09:08.758171+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}